Medical Therapy for Systemic Right Ventriles: A Systematic Review (Part 1) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease

Data Supplements

Table of Contents

Data Supplement 1. Literature Search Strategy: Beta Blockers, Angiotensin-Converting Enzyme Inhibitors, Aldosterone-Receptor Blockers, and Aldosterone Antagonists in Patients with Systemic Right Ventricles ................................................................. 2
Data Supplement 2. Full-Text Screened Articles ................................................................. 3
Data Supplement 3. Analysis of the Risk of Bias for PKVO₂ and Systemic Ventricular Function Measured by CMR Imaging ................................................................. 5
Data Supplement 4. Methodological Quality Assessment Based on the Cochrane Collaboration Risk of Bias Tool ................................................................. 7
Data Supplement 5. Methodological Quality Assessment of Cohort Studies Based on the Newcastle-Ottawa Scale ................................................................. 8
References ......................................................................................................................... 9
Data Supplement 1. Literature Search Strategy: Beta Blockers, Angiotensin-Converting Enzyme Inhibitors, Aldosterone-Receptor Blockers, and Aldosterone Antagonist in Patients with Systemic Right Ventricles

<table>
<thead>
<tr>
<th>Search set</th>
<th>Query</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>“heart single ventricle” OR &quot;Transposition of Great Vessels&quot;[Mesh] OR &quot;Heart Ventricles/abnormalities&quot;[MAJR] OR “univentricular heart” OR “double inlet left ventricle” OR “Tricuspid Atresia”[Mesh] OR &quot;Norwood Procedures&quot;[Mesh] OR &quot;Fontan Procedure&quot;[Mesh] OR &quot;Pulmonary Atresia&quot;[Mesh] OR “Transposition of the Great Vessels” OR “Dextro-Looped Transposition of the Great Arteries” OR “Congenitally corrected transposition of the great arteries” OR “Double outlet right ventricle” OR “Tricuspid Atresia” OR “Pulmonary Atresia” OR “Hypoplastic left heart syndrome” OR “Senning Operation” OR “Senning procedure” OR “Mustard operation” OR “Mustard procedure” OR “Atrial switch operation” OR &quot;L-transposition of the great arteries&quot; OR “D-transposition of the great arteries” OR “Pulmonary atresia” OR “Mitr al Atresia” OR “Unbalanced atrioventricular canal defect” OR Heterotaxy OR “atrial baffle repair”</td>
</tr>
<tr>
<td>#3</td>
<td>#1 AND #2</td>
</tr>
<tr>
<td>#4</td>
<td>#1 AND #2 AND Filters activated: Clinical Trial, Comparative Study, Controlled Clinical Trial, Meta-Analysis, Multicenter Study, Observational Study, Randomized Controlled Trial, Review, Systematic Reviews, Publication date from 1985/01/01 to 2014/12/31, Adolescent: 13-18 years, Adult: 19+ years, Young Adult: 19-24 years, Adult: 19-44 years, Middle Aged + Aged: 45+ years, Middle Aged: 45-64 years, Aged: 65+ years, 80 and over: 80+ years.</td>
</tr>
</tbody>
</table>
Data Supplement 3. Analysis of the Risk of Bias for PKVO₂ and Systemic Ventricular Function Measured by CMR Imaging

Begg and Mazumdar’s test (P-value): 0.333
Egger’s test (P-value): 0.438
CMR indicates cardiovascular magnetic resonance; EF, ejection fraction; and PKVO$_2$ ventilatory equivalent of oxygen.

**Begg and Mazumdar’s test (P-value): 0.483**

**Egger’s test (P-value): 0.332**
Data Supplement 4. Methodological Quality Assessment Based on the Cochrane Collaboration Risk of Bias Tool

<table>
<thead>
<tr>
<th></th>
<th>Van Der Bom et al. (1) 23247302</th>
<th>Dore et al. (2) 16216961</th>
<th>Dos et al. (3) 23972966</th>
<th>Therrien et al. (4) 18672299</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td><img src="#" alt="Green" /></td>
<td><img src="#" alt="Yellow" /></td>
<td><img src="#" alt="Yellow" /></td>
<td><img src="#" alt="Green" /></td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td><img src="#" alt="Green" /></td>
<td><img src="#" alt="Yellow" /></td>
<td><img src="#" alt="Green" /></td>
<td><img src="#" alt="Green" /></td>
</tr>
<tr>
<td>Blinding of personnel and participants (performance bias)</td>
<td><img src="#" alt="Green" /></td>
<td><img src="#" alt="Green" /></td>
<td><img src="#" alt="Red" /></td>
<td><img src="#" alt="Green" /></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td><img src="#" alt="Green" /></td>
<td><img src="#" alt="Yellow" /></td>
<td><img src="#" alt="Yellow" /></td>
<td><img src="#" alt="Green" /></td>
</tr>
<tr>
<td>Incomplete outcome data addressed (attrition bias)</td>
<td><img src="#" alt="Green" /></td>
<td><img src="#" alt="Red" /></td>
<td><img src="#" alt="Green" /></td>
<td><img src="#" alt="Red" /></td>
</tr>
<tr>
<td>Free of selective reporting (reporting bias)</td>
<td><img src="#" alt="Green" /></td>
<td><img src="#" alt="Green" /></td>
<td><img src="#" alt="Green" /></td>
<td><img src="#" alt="Green" /></td>
</tr>
<tr>
<td>Free of other bias</td>
<td><img src="#" alt="Red" /></td>
<td><img src="#" alt="Red" /></td>
<td><img src="#" alt="Red" /></td>
<td><img src="#" alt="Red" /></td>
</tr>
</tbody>
</table>

Low risk of bias  Unclear risk of bias  High risk of bias
Data Supplement 5. Methodological Quality Assessment of Cohort Studies Based on the Newcastle-Ottawa Scale

<table>
<thead>
<tr>
<th>Representativeness*</th>
<th>Hetcher et al. (5) 11230861</th>
<th>Tutarel et al. (6) 20843567</th>
<th>Giardini et al. (7) 21882492</th>
<th>Doughan et al. (8) 17317376</th>
<th>Boullal et al. (9) 20519056</th>
<th>Josephson et al. (10) 16835671</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selection of non-exposed†</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ascertainment of exposure‡</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Outcome not present at study recruitment§</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Comparability║</td>
<td>0</td>
<td>N/A</td>
<td>0</td>
<td>NA</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Assessment of outcome¶</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Follow-up long enough#</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Rate of response**</td>
<td>1</td>
<td>N/A</td>
<td>1</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Overall quality score††</td>
<td>5</td>
<td>7</td>
<td>4</td>
<td>6</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

*Representativeness of the exposed cohort (0,1); †Selection of the controls (0, 1, N/A); ‡Ascertainment of exposure (e.g., medical records) (0, 1, N/A); §Outcome of interest not present at start of study (0, 1); ║Comparability of cases and controls for most important factor and additional factors (0, 1, 2, N/A); ¶Assessment of outcome (e.g., medical records) (0, 1, N/A); #Follow-up long enough, >4 months (0, 1, N/A); **Same nonresponse rate for both groups (0, 1, N/A); ††Total: minimum=1, maximum=9 stars. N/A indicates not applicable.
References


